Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Queensland Health
Healthtrust
Cerilliant
Harvard Business School
AstraZeneca
Boehringer Ingelheim
Daiichi Sankyo
Julphar
Baxter

Generated: August 17, 2017

DrugPatentWatch Database Preview

Par Pharm Inc Company Profile

« Back to Dashboard

What is the competitive landscape for PAR PHARM INC, and when can generic versions of PAR PHARM INC drugs launch?

PAR PHARM INC has twenty-three approved drugs.

There is one US patent protecting PAR PHARM INC drugs. There are seven tentative approvals on PAR PHARM INC drugs.

There are nine patent family members on PAR PHARM INC drugs in eight countries.

Summary for Applicant: Par Pharm Inc

Patents:1
Tradenames:22
Ingredients:22
NDAs:23
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Par Pharm Inc
MORPHINE SULFATE
morphine sulfate
CAPSULE, EXTENDED RELEASE;ORAL200812-003Nov 10, 2011ABRXNoNo► Subscribe► Subscribe► Subscribe
Par Pharm Inc
BALSALAZIDE DISODIUM
balsalazide disodium
TABLET;ORAL206336-001Sep 8, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
Par Pharm Inc
AMLODIPINE BESYLATE AND VALSARTAN
amlodipine besylate; valsartan
TABLET;ORAL090011-004Mar 28, 2013ABRXNoNo► Subscribe► Subscribe► Subscribe
Par Pharm Inc
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE
amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil
TABLET;ORAL206137-003Oct 26, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Par Pharm Inc
ENTECAVIR
entecavir
TABLET;ORAL206294-001Nov 23, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Par Pharm Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Par Pharm Inc
ACCOLATE
zafirlukast
TABLET;ORAL020547-003Sep 17, 1999► Subscribe► Subscribe
Par Pharm Inc
ACCOLATE
zafirlukast
TABLET;ORAL020547-003Sep 17, 1999► Subscribe► Subscribe
Par Pharm Inc
ACCOLATE
zafirlukast
TABLET;ORAL020547-001Sep 26, 1996► Subscribe► Subscribe
Par Pharm Inc
ACCOLATE
zafirlukast
TABLET;ORAL020547-003Sep 17, 1999► Subscribe► Subscribe
Par Pharm Inc
ACCOLATE
zafirlukast
TABLET;ORAL020547-001Sep 26, 1996► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for PAR PHARM INC drugs

Drugname Dosage Strength Tradename Submissiondate
zafirlukast
Tablets10 mg and 20 mg
ACCOLATE
2/29/2008

International Patent Family for Par Pharm Inc Drugs

Country Document Number Estimated Expiration
Australia2006240490► Subscribe
Canada2605413► Subscribe
Mexico2007013118► Subscribe
Japan5378788► Subscribe
Japan2008538560► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Par Pharm Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00478Netherlands► SubscribePRODUCT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN AMLODIPINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER AMLODIPINEBESILAAT; REGISTRATION NO/DATE: EU/1/10/648/001-028 20101007
2014 00048Denmark► SubscribePRODUCT NAME: KOMBINATION AF ROSUVASTATIN OG EZETIMIBE ELLER FARMACEUTISK ACCEPTABLE SALTE DERAF, HERUNDER ROSUVASTATIN SOM ZINK; NAT. REG. NO/DATE: 52921, 52922, 52923 20140820; FIRST REG. NO/DATE: NO 13-9663, 13-9664, 13-9665 20140724
00445Netherlands► SubscribePRODUCT NAME: VALSARTAN, AMLODIPINE EN HYDROCHLOORTHIAZIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/09/569/001-060 20091016
00528Netherlands► SubscribePRODUCT NAME: COMBINATIE VAN ALISKIREN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, AMLODIPINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN HYDROCHLOORTHIAZIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; NATL. REGISTRATION NO/DATE: EU/1/11/730/001-060 20111122; FIRST REGISTRATION: CH 61678 01-05 20110705
C0043France► SubscribePRODUCT NAME: ROSUVASTATIN; NAT. REGISTRATION NO/DATE: NL 28 274 20030611; FIRST REGISTRATION: NL - 26872 20021106
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Novartis
Argus Health
Medtronic
McKinsey
Deloitte
Cipla
AstraZeneca
Federal Trade Commission
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot